1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNew Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (R01 - Clinical Trial Optional) is sponsored by National Institutes of Health. Funds research to develop advanced glucose control systems integrating AI/ML for diabetes management.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (R01 - Clinical Trial Optional) - Federal Grant New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (R01 - Clinical Trial Optional) The summary for the New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (R01 - Clinical Trial Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants. com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact .
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant. New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (R01 - Clinical Trial Optional): The purpose of this funding opportunity is to support research addressing barriers that limit progress toward more effective open- and closed-loop diabetes control systems.
This may include research that addresses: 1) innovation of sensing relevant analytes/physiologic signals; 2) novel formulation and delivery of hormones; 3) artificial intelligence (AI)/machine learning (ML)-driven tools/algorithms; and 4) digital twin modeling to augment decision support and automated control systems with the goal of improving glycemic control, reducing burden of care, and enhancing quality of life of people with T1D].
This NOFO is associated with the Special Diabetes Program (https://www. niddk. nih.
gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (R01 - Clinical Trial Optional) National Institutes of Health (HHS-NIH11) Funding Opportunity Number: Current Application Deadline: Original Application Deadline: Maximum Federal Grant Award: Minimum Federal Grant Award: Expected Number of Awards: Cost Sharing or Matching: Applicants Eligible for this Grant State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Grant Announcement Contact Division of Diabetes, Endocrinology and Metabolic Diseases Similar Government Grants • Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Compl...
• Cooperative Centers for Experimental Hematology (CCEHs) (U54- Clinical Trial Not Allowed) • Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney ... • Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury...
• Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional) • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes • Molecular Therapy Core Centers • Pilot and Feasibility Program in Human Islet Biology More Grants from the National Institutes of Health • Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiologi...
• Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) • Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not ... • Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) • Silvio O.
Conte Centers for Basic Neuroscience or Translational Mental Health Research (P5... Federal Grants by Category Grants for Single Mothers Small Business Grants for Women Federal Grants for College Federal Tuition Assistance
According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments. Confirm the full requirements in the official notice before applying.
New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (R01 - Clinical Trial Optional) is funded by National Institutes of Health. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article